2023. Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s135. DOI:https://doi.org/10.25251/skin.7.supp.135.